DaVita (DVA)
(Delayed Data from NYSE)
$138.05 USD
+1.20 (0.88%)
Updated Mar 28, 2024 04:00 PM ET
After-Market: $138.05 0.00 (0.00%) 7:58 PM ET
1-Strong Buy of 5 1
A Value D Growth B Momentum B VGM
Price, Consensus and EPS Surprise
DVA 138.05 +1.20(0.88%)
Will DVA be a Portfolio Killer in March?
Zacks Investment Research is releasing its prediction for DVA based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for DVA
McKesson (MCK) Hits 52-Week High: What's Driving the Stock?
Chemed (CHE) Up 2.5% Since Last Earnings Report: Can It Continue?
DVA: What are Zacks experts saying now?
Zacks Private Portfolio Services
GE HealthCare's (GEHC) PVA to Aid in Capturing Prostate Volume
3 Reasons to Retain Inogen (INGN) Stock in Your Portfolio
Here's Why You Should Add Lantheus (LNTH) to Your Portfolio
Other News for DVA
DaVita Stock Is A Hold As It Expands In Latin America
IXJ: Healthcare Sector Dashboard For March
Noteworthy Tuesday Option Activity: DVA, X, CYRX
The American Diabetes Association and DaVita Strengthen Alliance to Tackle Chronic Disease Head-On
DaVita Inc. to Participate in the Barclays Global Healthcare Conference 2024